Association between non-alcoholic fatty liver disease and liver function/injury markers with metabolic syndrome components in class III obese individuals

Revista da Associacao Medica Brasileira

Volumn 58, Issue 3, 2012, Pages 288-293

  Chaves, Gabriela Villaça ^a   de Souza, Daiane Spitz ^a   Pereira, Silvia Elaine ^b   Saboya, Carlos José ^b   Peres, Wilza Arantes Ferreira ^c  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b Carlos Saboya Clinic   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Fatty liver; Metabolic syndrome X; Obesity

Indexed keywords

BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD; BODY MASS; FATTY LIVER; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MORBID OBESITY; NUCLEAR MAGNETIC RESONANCE IMAGING; SEVERITY OF ILLNESS INDEX;

ADULT; BIOLOGICAL MARKERS; BODY MASS INDEX; FATTY LIVER; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, MORBID; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84864860189     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0104-4230(12)70197-5     Document Type: Article

References (41)

1. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5:27-42.
2. Clain DJ, Lefkowitch JH. Fatty liver disease in morbid obesity. Gastroenterol Clin North Am. 1987;16:239-52.
3. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-61.
4. Ruhl CE, Everhart JE. Epidemiology of non-alcoholic fatty liver. Clin Liver Dis. 2004;8:501-19.
5. Luyckx FH, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222-6.
6. Bitencourt AGV, Cotrim HP, Alves E, Almeida AM, Barbosa DBV, Santos AS, et al. Doença hepática gordurosa não alcoólica: características clínicas e histológicas em obesos graves submetidos à cirurgia bariátrica. Acta Gastroenterol Latinoam. 2007;37:224-30.
7. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab. 2002;16:703-16.
8. Adams LA, Lymp JF, St Sauver J, Sanderson SO, lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129:113-21.
9. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, et al. Increased prevalence of cardiovascular disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med. 2006;23:403-9.
10. Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;19:854-8.
11. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. World Health Organ Tech Rep Ser. 1998;894:1-253.
12. Cuppari L, Sampaio, LR, Baxmann A, Kamimura MA. Avaliação nutricional. In: Cuppari L. Guias de medicina ambulatorial e hospitalar. Nutrição clínica no adulto. UNIFESP. São Paulo: Manole; 2002. p. 89-127.
13. Empana JP, Ducimetieri P, Charles MA, Jouven X. Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris prospective study I. Circulation. 2004;110:2781-5.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
15. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian metabolic syndrome study. Diabetes Res Clin Prac. 2006;72:219-20.
16. Buccini GS, Wolfthal DL. Valores de corte para índices de insulinorresistencia, insulinosensibilidad e insulinosecreción derivados de la fórmula HOMA y del programa HOMA2. Interpretación de los datos. Rev Argent Endocrinol Metab. 2008;45:3-21.
17. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck study diabetes. 1998;47:1643-9.
18. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care. 2000;23:171-5.
19. The third report of the National Cholesterol Education Program (NCEP). Expert panel on detection. Evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285:2486-97.
20. Ferreira VSG, Pernambuco RB, Lopes EP, Morais CN, Rodrigues MC, Arruda MJ, et al. Frequência e fatores de risco associados à doença hepática gordurosa não alcoólica em pacientes com diabetes melito tipo 2. Arq Bras Endocrinol Metab. 2010;54:362-8.
21. Soler GLN, Silva AWSM, Silva VCG, Teixeira RJ. Doença hepática gordurosa não-alcoólica: associação com síndrome metabólica e fatores de risco cardiovascular. Rev SOCERJ. 2008;21:94-100.
22. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-40.
23. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513-7.
24. Stranges S, Dorn JM, Muti P, Freudeheim JL, Farinaro E, Russel M, et al. Body fat distribution, relative weight, and liver enzyme levels: a population-based study. Hepatology. 2004;39:754-63.
25. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med. 1995;27:435-8.
26. Björntorp, P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001;2:73-86.
27. Yoo HJ, Park MS, Lee CH, Yang SJ, Kim TN, Lim KI, et al. Cutoff points of abdominal obesity indices in screening for non-alcoholic fatty liver disease in Asians. Liver Int. 2010;30:1189-96.
28. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, et al. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003;18:588-94.
29. Boza C, Riquelme A, Ibañez L, Duarte I, Norero E, Viviani P, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148-53.
30. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91-100.
31. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-23.
32. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 2000;26:98-106.
33. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002;87:3023-8.
34. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, Lasio R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498-504.
35. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Fiorello, S et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease J Clin Endocrinol Metab. 2005;90:1578-82.
36. Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006; 91:4753-61.
37. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-19.
38. Ruano M, Silvestre V, Castro R, García-Lescún MC, Aguirregoicoa E, Marco A, et al. HOMA, QUICKI and MFfm to measure insulin resistance in morbid obesity. Obes Surg. 2006;16:549-53.
39. Geloneze B, Tambascia MA. Avaliação laboratorial e diagnóstico da resistência insulínica. Arq Bras Endocrinol Metab. 2006;50:208-15.
40. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third national health and nutrition survey (NHANES III). Am J Med Sci. 2005;329:111-6.
41. Koller T, Kellerová J, Hlavaty T, Huorka M, Payer J. Prevalence of liver disease markers among patients with metabolic risk factors. Vnitr Lek. 2010;56:183-9